Expansions into the US from Canadian cannabis companies offer investors an opportunity to see returns from rapidly adopting pocket markets all over the country. Now, Aphria (TSX:APH; OTCQB:APHQF) is adding to the list in the state of Florida with Liberty Health Sciences (CSE:LHS).
On July 26, Liberty Health officially began trading on the Canadian Securities Exchange (CSE) and and entered into an agreement to pick up the Chestnut Hill Tree Farm, a small “pre-revenue” company set to produce licensed medical marijuana in Florida.
“We always saw Florida as a tremendous opportunity because of the sheer population size,” CEO George Scorsis told The Palm Beach Post.
“Aphria’s success story is no longer limited to Canada”, CEO Vic Neufeld said in the statement. “Aphria’s footprint expansion provides significant growth opportunities for our shareholders.

More opportunity in the growing Florida market

Reporting from The Palm Beach Post indicates that the Florida Department of Health has 23,350 patients registered for cannabis. Patients in the state must obtain a recommendation from their doctors to be treated with cannabis.
Scorsis said the company will be the “lowest-cost producer in Florida.”
On July 24, Scorsis was named CEO following his stint as president of Mettrum Health, a Canadian Licensed Producer, which got acquired by Canopy Growth (TSX:WEED) for $430 million.
Earlier this year Mettrum went through a recall process for a batch of product in which unregistered pesticides were found.
“The application of pest control products not registered for use on cannabis at Mettrum was inexcusable,” Bruce Linton founder and CEO of Canopy wrote in a letter to investors and consumers.
In the end, the voluntary recall was only a type three one, meaning it was not likely to “cause any adverse health” damage.

Investor Takeaway

In a recent interview with the Investing News Network (INN), cannabis analyst Neal Gilmer said this year the company has executed based on what they had communicated before.
“[T]hey put positive financial results. They beat all expectations that I was aware of and they beat the top line; revenues were above my expectations and consensus estimates,” Gilmer told INN.
Ever since Aphria began trading on the TSX in March, the company’s share price has declined 7.2 percent. Last week alone its stock took a 10.63 percent hit. As of 12:30 p.m. EST on Friday, shares of Aphria were trading at $5.82.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less


Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less